Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Levy-Lahad, E. Friedman, E. Friedman (2007)Cancer risks among BRCA1 and BRCA2 mutation carriers
British Journal of Cancer, 96
Marie Søgaard, S. Kjær, S. Gayther (2006)Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention
Acta Obstetricia et Gynecologica Scandinavica, 85
C. Apicella, L. Andrews, S. Hodgson, S. Fisher, C. Lewis, E. Solomon, K. Tucker, M. Friedlander, A. Bankier, M. Southey, D. Venter, J. Hopper (2003)Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)
Breast Cancer Research : BCR, 5
(2003)Surveillance, epidemiology, and end results SEER program stat database: incidence–SEER 9 regs public-use
A. Antoniou, Rachel Hardy, L. Walker, D. Evans, A. Shenton, R. Eeles, S. Shanley, G. Pichert, L. Izatt, S. Rose, F. Douglas, D. Eccles, Patrick Morrison, J. Scott, R. Zimmern, D. Easton, Paul Pharoah (2008)Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
Journal of Medical Genetics, 45
Sining Chen, G. Parmigiani (2007)Meta-analysis of BRCA1 and BRCA2 penetrance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 11
N. Lindor, M. McMaster, Carl Lindor, M. Greene (2008)Concise handbook of familial cancer susceptibility syndromes - second edition.
Journal of the National Cancer Institute. Monographs, 38
B. Larsen (2010)[Colorectal cancer screening].
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 130 20
D. Hosmer, S. Lemeshow (1991)Applied Logistic Regression
S. Wacholder, P. Hartge, R. Prentice, M. García-Closas, Spencer Feigelson, W. Diver, M. Thun, David Cox, S. Hankinson, P. Kraft, B. Rosner, C. Berg, L. Brinton, J. Lissowska, M. Sherman, R. Chlebowski, C. Kooperberg, R. Jackson, D. Buckman, Peter Hui, R. Pfeiffer, K. Jacobs, G. Thomas, R. Hoover, M. Gail, S. Chanock, D. Hunter, Genetics, G.-C, R. Pfeiffer, Kaiser Permanente, Denver, H. Inserm, France Lyon, Biostatistics, In Boston, Poland, Silver Spring, P. AddressPerformance of Common Genetic Variants in Breast-cancer Risk Models
N. Lindor, R. Lindor, C. Apicella, J. Dowty, A. Ashley, Katherine Hunt, B. Mincey, Marcia Wilson, M. Smith, J. Hopper (2007)Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models
Familial Cancer, 6
R. Milne, A. Osorio, T. Cajal, A. Vega, G. Llort, M. Hoya, O. Díez, M. Alonso, C. Lázaro, I. Blanco, Ana Sánchez-de-Abajo, T. Caldés, A. Blanco, B. Graña, M. Durán, E. Velasco, I. Chirivella, E. Cardeñosa, M. Tejada, E. Beristain, M. Miramar, M. Calvo, E. Martínez, C. Guillén, R. Salazar, C. Román, A. Antoniou, M. Urioste, J. Benítez (2008)The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14 9
G. Evans, A. Shenton, E. Woodward, F. Lalloo, A. Howell, E. Maher (2008)Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
BMC Cancer, 8
A. Antoniou, F. Durocher, Paula Smith, J. Simard, D. Easton (2005)BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
Breast Cancer Research, 8
F. Marroni, P. Aretini, E. D'andrea, M. Caligo, L. Cortesi, A. Viel, E. Ricevuto, M. Montagna, G. Cipollini, M. Federico, M. Santarosa, P. Marchetti, J. Bailey-Wilson, G. Bevilacqua, G. Parmigiani, S. Presciuttini (2004)Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations
European Journal of Human Genetics, 12
S. Narod, K. Offit (2005)Prevention and management of hereditary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 8
F. Couch, Michelle Deshano, M. Blackwood, K. Calzone, J. Stopfer, Lisa Campeau, A. Ganguly, T. Rebbeck, B. Weber, L. Jablon, M. Cobleigh, K. Hoskins, J. Garber (1997)BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
The New England journal of medicine, 336 20
T. Frank, A. Deffenbaugh, J. Reid, M. Hulick, B. Ward, B. Lingenfelter, K. Gumpper, T. Scholl, S. Tavtigian, D. Pruss, G. Critchfield (2002)Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 6
A. Benson, T. Abrams, E. Ben-Josef, P. Bloomston, J. Botha, B. Clary, A. Covey, S. Curley, M. D'Angelica, Rene Davila, W. Ensminger, J. Gibbs, D. Laheru, M. Malafa, J. Marrero, S. Meranze, S. Mulvihill, James Park, J. Posey, J. Sachdev, R. Salem, E. Sigurdson, C. Sofocleous, J. Vauthey, A. Venook, L. Goff, Y. Yen, A. Zhu (2009)NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Journal of the National Comprehensive Cancer Network : JNCCN, 7 4
D. Berry, E. Iversen, D. Gudbjartsson, E. Hiller, J. Garber, B. Peshkin, C. Lerman, P. Watson, H. Lynch, S. Hilsenbeck, W. Rubinstein, K. Hughes, G. Parmigiani (2002)BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 11
G. Parmigiani, D. Berry, O. Aguilar (1998)Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.
American journal of human genetics, 62 1
J. Dunn (1997)Colorectal cancer screening.
The New Zealand medical journal, 110 1055
A number of models have been developed to predict the probability that a person carries a detectable germline mutation in the BRCA1 or BRCA2 genes. Their relative performance in a clinical setting is variable. To compare the performance characteristics of a web-based BRCA1/BRCA2 gene mutation prediction model: the PENNII model ( www.afcri.upenn.edu/itacc/penn2 ), with studies done previously at our institution using four other models including LAMBDA, BRCAPRO, modified PENNI (Couch) tables, and Myriad II tables collated by Myriad Genetics Laboratories. Proband and family cancer history data were analyzed from 285 probands from unique families (27 Ashkenazi Jewish; 277 female) seen for genetic risk assessment in a multispecialty tertiary care group practice. All probands had clinical testing for BR.CA1 and BRCA2 mutations conducted in the same single commercial laboratory. The performance for PENNII results were assessed by the area under the receiver operating characteristic curve (AUC) of sensitivity versus 1-specificity, as a measure of ranking. The AUCs of the PENNII model were higher for predicting BRCA1 than for BRCA2 (81 versus 72%). The overall AUC was 78.7%. PENN II model for BRCA1/2 prediction performed well in this population with higher AUC compared with our experience using four other models. The ease of use of the PENNII model is compatible with busy clinical practices.
Familial Cancer – Springer Journals
Published: May 29, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.